Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults
NCT07824271
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Researchers are testing an investigational medicine called ALZ-507 in healthy adults between 50 and 75 years of age. The purpose of this study is to learn: Assess if oral ALZ-507 is safe What side effects may occur How the body absorbs ALZ-507 Whether food affects how ALZ-507 is absorbed How much ALZ-507 reaches the blood, cerebrospinal fluid, and urine Participants will receive either ALZ-507 or a placebo. Some participants will receive a single dose, while others will receive daily doses for two weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Participants Study
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Alzheon Inc.
- Last updated on ClinicalTrials.gov
- September 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Quotient Sciences · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.